secwatch.observer — SEC 8-K summary
======================================

Issuer:     HYPERION DEFI, INC. (HYPD)
CIK:        0001682639
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001104659-23-089813
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eyenovia Q2 net loss narrows to $6.2M; first Mydcombi sale post-FDA approval
----------------------------------------------------------------------------

- Net loss for Q2 2023 was $(6.2)M ($0.16 per share), improved from $(7.2)M ($0.22) in Q2 2022; cash $17.5M as of June 30.
- First commercial sale of Mydcombi to Dr. Nathan Radcliffe; national launch expected in early 2024 after FDA approval.
- Apersure (Microline) presbyopia program advances; FDA provided clear path; registration batch manufacture planned for Q4 2023.
- R&D expenses $2.8M (down from $3.6M), G&A $3.1M (down from $3.5M); total op expenses $6.0M vs $7.1M YoY.
- Added to Russell 2000 and 3000 indexes; licensing partners Bausch+Lomb and Arctic Vision enrolling Phase 3 trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682639/000110465923089813/0001104659-23-089813-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682639/000110465923089813/tm2323259d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-089813

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer